LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
LeonaBio announced that its lead drug candidate, lasofoxifene, will be highlighted in several presentations at Dava Oncology's 4th Summit on Breast Cancer. The presentations will emphasize lasofoxifene's potential as a novel treatment for ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, including progress in its pivotal Phase 3 EL…